LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

Lantheus Holdings Inc

Suletud

SektorTervishoid

56.71 2.03

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

55

Max

56.94

Põhinäitajad

By Trading Economics

Sissetulek

5.8M

79M

Müük

5.3M

378M

P/E

Sektori keskmine

14.936

35.724

Kasumimarginaal

20.832

Töötajad

808

EBITDA

7.7M

123M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+54.74% upside

Turustatistika

By TradingEconomics

Turukapital

-1.1B

3.8B

Eelmine avamishind

54.68

Eelmine sulgemishind

56.71

Uudiste sentiment

By Acuity

25%

75%

44 / 372 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Lantheus Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. aug 2025, 22:51 UTC

Tulu

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27. aug 2025, 23:57 UTC

Tulu

Trip.com Group 1H Rev $4.01B

27. aug 2025, 23:57 UTC

Tulu

Trip.com Group 1H Adj EPS $1.84

27. aug 2025, 23:57 UTC

Tulu

Trip.com Group 1H EPS $1.82

27. aug 2025, 23:50 UTC

Market Talk

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27. aug 2025, 23:39 UTC

Tulu

Correction to Nvidia Earnings Article -- WSJ

27. aug 2025, 22:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. aug 2025, 22:59 UTC

Market Talk

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27. aug 2025, 22:58 UTC

Tulu

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27. aug 2025, 22:57 UTC

Tulu

South32 FY Free Cash Flow $192 Million

27. aug 2025, 22:56 UTC

Tulu

South32 FY Total Capital Expenditure $1.35 Billion

27. aug 2025, 22:56 UTC

Tulu

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27. aug 2025, 22:55 UTC

Tulu

South32 Net Cash $123 Million at June 30

27. aug 2025, 22:54 UTC

Tulu

South32: Focused on Maintaining Strong Operating Momentum

27. aug 2025, 22:53 UTC

Tulu

South32: $144 Million Remains to be Returned to Shareholders Under Program

27. aug 2025, 22:53 UTC

Tulu

South32 Extends Capital Management Program for 12 Months

27. aug 2025, 22:52 UTC

Tulu

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27. aug 2025, 22:51 UTC

Tulu

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27. aug 2025, 22:51 UTC

Tulu

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27. aug 2025, 22:50 UTC

Tulu

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27. aug 2025, 22:50 UTC

Tulu

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27. aug 2025, 22:45 UTC

Tulu

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27. aug 2025, 22:44 UTC

Tulu

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27. aug 2025, 22:44 UTC

Tulu

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27. aug 2025, 22:43 UTC

Tulu

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27. aug 2025, 22:43 UTC

Tulu

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27. aug 2025, 22:42 UTC

Tulu

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27. aug 2025, 22:42 UTC

Tulu

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27. aug 2025, 22:40 UTC

Tulu

Sandfire Resources Net Debt $123 Million at June 30

27. aug 2025, 22:40 UTC

Tulu

Sandfire Resources FY Underlying Ebitda $527.7 Million

Võrdlus sarnastega

Hinnamuutus

Lantheus Holdings Inc Prognoos

Hinnasiht

By TipRanks

54.74% tõus

12 kuu keskmine prognoos

Keskmine 86.13 USD  54.74%

Kõrge 110 USD

Madal 63 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Lantheus Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

9 ratings

7

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

79.24 / 103.64Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Neutral Evidence

Sentiment

By Acuity

44 / 372 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.